---
title: "Inaxaplin (VX-147) in APOL1-mediated kidney disease: VX20-147-008"
description: "Formulary evidence on Inaxaplin (VX-147) in APOL1-mediated kidney disease: VX20-147-008. Covers Objective, Location and study date, Study design, Eligibility criteria, Treatment, Study outcomes, and 3 further headings. 37 evidence topics quoted from 1 source."
canonical: "https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/clinical-evidence/vx20-147-008"
published: "2026-11-15T23:17:22-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Inaxaplin (VX-147) in APOL1-mediated kidney disease: VX20-147-008

<a id="heading-3.1.5"></a>

## 3.1.5 VX20-147-008

<a id="heading-3.1.5.1"></a>

### 3.1.5.1 Objective

<a id="topic-3.1.5.1-1"></a>

#### Aims of the two phase 1 studies

> “We conducted two phase 1 studies evaluating the safety, tolerability, and pharmacokinetics of single-ascending doses (SAD) and multiple-ascending doses (MAD) of inaxaplin in healthy participants.”

Source: [Egbuna et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11006409/)

<a id="topic-3.1.5.1-2"></a>

#### Higher-dose study VX20-147-008

> “To provide additional clinical information on the safety of higher doses of inaxaplin, a second phase 1 study of inaxaplin (Study VX20-147-008 or Study 2) evaluated single ascending doses of 90 mg up to 165 mg and multiple ascending doses of 60 mg up to 120 mg once daily in healthy participants.”

Source: [Egbuna et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11006409/)

<a id="topic-3.1.5.1-3"></a>

#### Primary objective: safety and tolerability

> “The primary objective for Parts A and B of both phase 1 studies was to determine safety and tolerability based on assessment of adverse events (AEs), clinical laboratory assessments (serum chemistry, hematology, coagulation, and urinalysis), standard 12-lead ECG measures (performed in triplicate), and vital signs.”

Source: [Egbuna et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11006409/)

<a id="heading-3.1.5.2"></a>

### 3.1.5.2 Location and Study Date

<a id="topic-3.1.5.2-1"></a>

#### Site and dates of Study 2

> “Study 2 was conducted at one site in the United States (Salt Lake City, UT) between August 2020 and March 2021.”

Source: [Egbuna et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11006409/)

<a id="topic-3.1.5.2-2"></a>

#### Ethics approval

> “The study protocols were approved by the Advarra Institutional Review Board in the United States (Advarra IRB Identifiers: Pro00035356, Pro00034297, and Pro00044276).”

Source: [Egbuna et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11006409/)

<a id="heading-3.1.5.3"></a>

### 3.1.5.3 Study Design

<a id="topic-3.1.5.3-1"></a>

#### Randomized, double-blind, placebo-controlled SAD/MAD design

> “We conducted two phase 1, randomized, double-blind, placebo-controlled SAD/MAD studies of inaxaplin in healthy participants.”

Source: [Egbuna et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11006409/)

<a id="topic-3.1.5.3-2"></a>

#### Part A single ascending doses and Part B multiple ascending doses

> “Part A of both phase 1 studies was designed to evaluate the safety and tolerability of single oral ascending doses of inaxaplin administered to healthy participants.”
> “Part B of both phase 1 studies was designed to evaluate the safety and tolerability of multiple oral ascending doses of inaxaplin administered to healthy participants.”

Source: [Egbuna et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11006409/)

<a id="topic-3.1.5.3-3"></a>

#### Unique participants per cohort and safety follow-up

> “All SAD and MAD cohorts included unique participants. There was no cross-over of participants within or across study cohorts. All participants had a Safety Follow-up Visit 7–10 days after the last dose of study drug.”

Source: [Egbuna et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11006409/)

<a id="topic-3.1.5.3-4"></a>

#### Repetition of two MAD cohorts

> “The inaxaplin 60 mg once daily and 90 mg once daily MAD cohorts in Study 2 were repeated with a distinct set of participants.”

Source: [Egbuna et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11006409/)

<a id="topic-3.1.5.3-5"></a>

#### Sponsor design of the trials

> “These trials were designed by Vertex Pharmaceuticals.”

Source: [Egbuna et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11006409/)

<a id="heading-3.1.5.4"></a>

### 3.1.5.4 Eligibility Criteria

<a id="topic-3.1.5.4-1"></a>

#### Healthy adults of non-childbearing potential

> “In both studies, we enrolled healthy men and women of non-childbearing potential who were at least 18 years of age with body weight of >50 kg and body mass index (BMI) 18.0 to 32.0 kg/m2.”
> “was defined by no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurement, standard 12-lead electrocardiogram (ECG), and clinical laboratory tests.”

Source: [Egbuna et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11006409/)

<a id="heading-3.1.5.5"></a>

### 3.1.5.5 Treatment

<a id="topic-3.1.5.5-1"></a>

#### Single doses of 90 to 165 mg or placebo in Part A of Study 2

> “In Study 2, participants were randomized 3:1 to receive a single dose of inaxaplin (90 mg, 135 mg, 165 mg) or placebo.”

Source: [Egbuna et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11006409/)

<a id="topic-3.1.5.5-2"></a>

#### Multiple doses for 14 days or placebo in Part B of Study 2

> “In Study 2, participants were randomized 3:1 to receive multiple doses of inaxaplin (60 mg once daily, 90 mg once daily, 120 mg once daily) or placebo for 14 days.”

Source: [Egbuna et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11006409/)

<a id="heading-3.1.5.6"></a>

### 3.1.5.6 Study Outcomes

<a id="heading-3.1.5.6.1"></a>

#### 3.1.5.6.1 Rationale for Using Safety and Tolerability Assessments as the Primary Endpoints

<a id="topic-3.1.5.6.1-1"></a>

##### Primary safety and tolerability endpoints at higher doses

> “To provide additional clinical information on the safety of higher doses of inaxaplin, a second phase 1 study of inaxaplin (Study VX20-147-008 or Study 2) evaluated single ascending doses of 90 mg up to 165 mg and multiple ascending doses of 60 mg up to 120 mg once daily in healthy participants.”
> “The primary objective for Parts A and B of both phase 1 studies was to determine safety and tolerability based on assessment of adverse events (AEs), clinical laboratory assessments (serum chemistry, hematology, coagulation, and urinalysis), standard 12-lead ECG measures (performed in triplicate), and vital signs.”

Source: [Egbuna et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11006409/)

<a id="topic-3.1.5.6.1-2"></a>

##### Pharmacokinetic assessments

> “In both studies, we assessed plasma pharmacokinetic (PK) parameter estimates of inaxaplin (i.e., time of maximum concentration [tmax], maximum observed concentration [Cmax], area under the concentration vs. time curve from the time of dosing to 24 h [AUC0–24h], terminal phase half-life [t½], apparent volume of distribution [V/F], and apparent clearance at steady-state [CLss/F]) after multiple oral ascending doses of inaxaplin derived from plasma concentration-time data. We also assessed urine PK parameter estimates.”

Source: [Egbuna et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11006409/)

<a id="heading-3.1.5.7"></a>

### 3.1.5.7 Statistical Analysis Description

<a id="heading-3.1.5.7.1"></a>

#### 3.1.5.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.5.7.1-1"></a>

##### Participants randomized and dosed across both studies

> “One hundred and seventy eight participants were randomized and received at least one dose of study drug in the SAD and MAD cohorts of the two phase 1 studies.”
> “There were 21 participants who received placebo in the SAD cohort and 23 participants who received placebo in the MAD cohort.”
> “There were 63 participants who received inaxaplin in the SAD cohort and 71 participants who received inaxaplin in the MAD cohort.”

Source: [Egbuna et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11006409/)

<a id="topic-3.1.5.7.1-2"></a>

##### Participants per group in the completed MAD cohorts of Study 2

> “Inaxaplin 60 mg once daily (N = 9)”
> “Inaxaplin 90 mg once daily (N = 9)”
> “Inaxaplin 120 mg once daily (N = 9)”
> “Placebo is pooled from MAD cohorts in Study 2 (except for the two MAD cohorts that were prematurely discontinued based on sponsor decision).”

Source: [Egbuna et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11006409/)

<a id="heading-3.1.5.7.2"></a>

#### 3.1.5.7.2 Description of Analysis Sets

<a id="topic-3.1.5.7.2-1"></a>

##### Safety set excluding the prematurely discontinued MAD cohorts

> “N, Safety Set sample size”
> “This table includes all participants in the MAD cohorts of Study 2 who were not prematurely discontinued and who received at least one dose of study drug.”
> “A summary of AEs for the SAD and MAD cohorts of both phase 1 studies is presented in Table 3; this table includes the two MAD cohorts in Study 2 that were prematurely discontinued by the sponsor due to ECG equipment malfunction and COVID-19 infection.”

Source: [Egbuna et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11006409/)

<a id="topic-3.1.5.7.2-2"></a>

##### Descriptive analyses, triplicate ECGs, and pooled analysis across cohorts

> “In both phase 1 studies, we used descriptive analyses on safety data including AEs, clinical laboratory assessments, vital signs, and ECGs.”
> “Since ECGs were performed in triplicate, the mean of each individual ECG parameter measurement (i.e., PR, RR, QRS, QT, QTcF, heart rate) at each specific visit and time point was used as the ECG for that specific visit and time point for summary purposes. In addition to analyses performed in the SAD and MAD cohorts separately for the two studies, we conducted a pooled analysis across cohorts.”

Source: [Egbuna et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11006409/)

<a id="heading-3.1.5.8"></a>

### 3.1.5.8 Results

<a id="heading-3.1.5.8.1"></a>

#### 3.1.5.8.1 Participant Disposition

<a id="topic-3.1.5.8.1-1"></a>

##### No discontinuations in the single-dose cohorts

> “There were no study drug discontinuations in the SAD cohorts in both studies as participants only received a single dose of study drug.”

Source: [Egbuna et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11006409/)

<a id="topic-3.1.5.8.1-2"></a>

##### Two MAD cohorts discontinued by sponsor decision

> “In the Study 2, 21 participants in two MAD cohorts discontinued treatment due to sponsor decision; this includes 12 participants (inaxaplin 60 mg once daily group: N = 9; placebo group: N = 3) who discontinued study drug due to ECG equipment malfunction and 9 participants (inaxaplin 90 mg once daily group: N = 7; placebo group: N = 2) who discontinued study drug due to the impact of the COVID-19 pandemic.”
> “Dosing in one cohort (inaxaplin 60 mg once daily MAD group: N = 9; placebo MAD group: N = 3) was paused to investigate an ECG finding in a single participant that was ultimately found to be due to ECG equipment malfunction (dosing was stopped prior to day 2 dose for the incident participant and prior to day 3 dose in all other participants). As dosing was interrupted, the cohort was discontinued per sponsor decision.”
> “Due to possible exposure to infection, the sponsor decided to discontinue the remainder of the cohort (inaxaplin 90 mg once daily MAD group: N = 7; placebo MAD group: N = 2) on day 2.”

Source: [Egbuna et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11006409/)

<a id="topic-3.1.5.8.1-3"></a>

##### Discontinuations for adverse events in Study 2

> “Participant in the inaxaplin 60 mg once daily treatment group discontinued study drug due to an AE of tachycardia; AE was mild in severity and considered by the investigator as not related to study drug.”
> “In Study 2, one participant in the inaxaplin 90 mg once daily MAD group discontinued treatment due to the AE of COVID-19 (as described above), which was moderate in severity, resolved without treatment, and was considered by the investigator as not related to inaxaplin (Table 3).”

Source: [Egbuna et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11006409/)

<a id="topic-3.1.5.8.1-4"></a>

##### Disposition pooled across Study 1 and Study 2

| Disposition | Placebo | Inaxaplin total |
| --- | --- | --- |
| Completed study drug (SAD only), n/N (%) | “21/21 (100.0)” | “63/63 (100.0)” |
| Completed study drug (MAD only), n/N (%) | “18/23 (78.3)” | “50/71 (70.4)” |
| Discontinued study drug (MAD only), n/N (%) | “5/23 (21.7)” | “21/71 (29.6)” |
| Discontinued for adverse event | “0” | “3/71 (4.2)” |
| Participant refused further dosing (not due to AE) | “0” | “1/71 (1.4)” |
| Other non-adherence | “0” | “1/71 (1.4)” |
| Sponsor decision | “5/23 (21.7)” | “16/71 (22.5)” |

Source: [Egbuna et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11006409/)

<a id="heading-3.1.5.8.2"></a>

#### 3.1.5.8.2 Baseline Characteristics

<a id="topic-3.1.5.8.2-1"></a>

##### Demographics pooled across Study 1 and Study 2

| Characteristic | Placebo (N = 44) | Inaxaplin total (N = 134) |
| --- | --- | --- |
| Male, n (%) | “41 (93.2)” | “128 (95.5)” |
| Female, n (%) | “3 (6.8)” | “6 (4.5)” |
| Age (years), mean (±SD) | “36.7 (11.3)” | “36.6 (11.6)” |
| BMI (kg/m2), mean (±SD) | “27.07 (3.14)” | “26.22 (3.30)” |
| White, n (%) | “30 (68.2)” | “94 (70.1)” |
| Black or African American, n (%) | “12 (27.3)” | “32 (23.9)” |
| Asian, n (%) | “0” | “1 (0.7)” |
| American Indian or Alaska Native, n (%) | “0” | “3 (2.2)” |
| Multiracial, n (%) | “1 (2.3)” | “4 (3.0)” |
| Other race, n (%) | “1 (2.3)” | “0” |
| Hispanic or Latino, n (%) | “10 (22.7)” | “21 (15.7)” |
| Not Hispanic or Latino, n (%) | “34 (77.3)” | “113 (84.3)” |

Source: [Egbuna et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11006409/)

<a id="topic-3.1.5.8.2-2"></a>

##### Age and comparability of groups

> “The mean (± standard deviation) age of all participants was 36.7 (±11.5) years. Demographics and baseline characteristics were similar across the inaxaplin and placebo groups.”

Source: [Egbuna et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11006409/)

<a id="heading-3.1.5.8.3"></a>

#### 3.1.5.8.3 Efficacy Results

<a id="topic-3.1.5.8.3-1"></a>

##### Dose proportionality and half-life up to 120 mg once daily

> “The PK of inaxaplin was generally dose proportional, and the variability in PK parameters was generally low and did not appear to change across the dose range (online Table S1). Half-life was consistent across both studies ranging from approximately 13.3 to 22.9 h, which supports once daily dosing (online Table S1).”
> “It exhibits dose proportional PK with low variability across doses up to 120 mg once daily for 14 days with a half-life ranging from 13.3 to 22.9 h.”

Source: [Egbuna et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11006409/)

<a id="topic-3.1.5.8.3-2"></a>

##### Renal clearance as a minor excretion pathway

> “Renal clearance was a minor excretion pathway for inaxaplin; dose adjustments are therefore not anticipated for the intended patient population which will include patients with renal function impairment (online Table S2).”

Source: [Egbuna et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11006409/)

<a id="heading-3.1.5.8.4"></a>

#### 3.1.5.8.4 Health-related Quality of Life and Patient-reported Outcomes

Not applicable.

<a id="heading-3.1.5.8.5"></a>

#### 3.1.5.8.5 Safety Results

<a id="topic-3.1.5.8.5-1"></a>

##### Adverse events in the completed MAD cohorts of Study 2

| n (%) | Placebo (N = 9) | Inaxaplin 60 mg once daily (N = 9) | Inaxaplin 90 mg once daily (N = 9) | Inaxaplin 120 mg once daily (N = 9) | Inaxaplin total (N = 27) |
| --- | --- | --- | --- | --- | --- |
| Participants with any AEs | “5 (55.6)” | “6 (66.7)” | “3 (33.3)” | “3 (33.3)” | “12 (44.4)” |
| Mild AEs | “4 (44.4)” | “6 (66.7)” | “3 (33.3)” | “3 (33.3)” | “12 (44.4)” |
| Moderate AEs | “1 (11.1)” | “0” | “0” | “0” | “0” |
| Participants with SAEs | “0” | “0” | “0” | “0” | “0” |
| AEs leading to treatment discontinuation | “0” | “1 (11.1)” | “0” | “0” | “1 (3.7)” |
| Headache | “0” | “2 (22.2)” | “1 (11.1)” | “2 (22.2)” | “5 (18.5)” |
| Palpitations | “1 (11.1)” | “0” | “1 (11.1)” | “0” | “1 (3.7)” |
| Abdominal pain | “1 (11.1)” | “0” | “0” | “1 (11.1)” | “1 (3.7)” |
| Diarrhea | “0” | “0” | “1 (11.1)” | “1 (11.1)” | “2 (7.4)” |

Source: [Egbuna et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11006409/)

<a id="topic-3.1.5.8.5-2"></a>

##### Adverse events in the two prematurely discontinued MAD cohorts

> “In the two MAD cohorts from Study 2 that were prematurely discontinued due to sponsor decision, there were eight AEs including four AEs of headache (one in the placebo group; three in the inaxaplin group), two AEs of COVID-19 (both in the inaxaplin group), one AE of fatigue (placebo group) and one AE of dyspnea (inaxaplin group).”

Source: [Egbuna et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11006409/)

<a id="topic-3.1.5.8.5-3"></a>

##### Tachycardia leading to discontinuation in Study 2

> “One participant in the inaxaplin 60 mg once daily MAD group in Study 2 discontinued treatment due to an AE of tachycardia (Table 5); this participant reported anxiety as an AE (of mild intensity) and reported similar instances of test anxiety in the past. The AE of tachycardia was considered mild in severity, resolved without treatment, and was considered by the investigator as not related to study drug.”

Source: [Egbuna et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11006409/)

<a id="topic-3.1.5.8.5-4"></a>

##### Adverse events pooled across Study 1 and Study 2

| n (%) | Placebo (N = 44) | Inaxaplin total (N = 134) |
| --- | --- | --- |
| Participants with any AEs | “10 (22.7)” | “33 (24.6)” |
| Mild AEs | “9 (20.5)” | “29 (21.6)” |
| Moderate AEs | “1 (2.3)” | “4 (3.0)” |
| Participants with SAEs | “0” | “0” |
| AEs leading to treatment discontinuation | “0” | “3 (2.2)” |
| Headache | “1 (2.3)” | “14 (10.4)” |
| Fatigue | “2 (4.5)” | “2 (1.5)” |
| Diarrhea | “0” | “4 (3.0)” |
| COVID-19 | “0” | “3 (2.2)” |
| Cough | “0” | “3 (2.2)” |
| Dyspepsia | “0” | “3 (2.2)” |

Source: [Egbuna et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11006409/)

<a id="topic-3.1.5.8.5-5"></a>

##### Severity, relatedness, and headache across both studies

> “All AEs were mild or moderate in severity. None of the AEs were considered by the investigator as related to inaxaplin. There were no serious adverse events (SAEs) (Table 3).”
> “Inaxaplin was generally well tolerated at single doses up to 165 mg and at multiple doses up to 120 mg once daily for 14 days.”
> “The incidence of headache was lower in participants treated with doses of inaxaplin ≤45 mg once daily (11.1%) than in those treated with doses of inaxaplin ≥60 mg once daily (18.5%).”

Source: [Egbuna et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11006409/)

<a id="topic-3.1.5.8.5-6"></a>

##### Laboratory values, vital signs, and ECG parameters

> “During the course of the SAD and MAD cohorts of both phase 1 studies, no clinically relevant trends were noted in any of the clinical laboratory results. Specifically, mean serum creatinine concentrations, serum lipid profile (i.e., total cholesterol, HDL cholesterol, LDL cholesterol, and triglyceride concentrations), and leukocyte counts were similar between the inaxaplin and placebo groups for all timepoints.”
> “There was no evidence of effects of inaxaplin on ECG parameters. There were no participants with a maximum QT interval corrected by Fridericia’s formula (QTcF; calculated from ECG assessments) interval >480 msec. No participants in the SAD or MAD cohorts had a QTcF interval increase >60 msec.”

Source: [Egbuna et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11006409/)

<a id="heading-3.1.5.9"></a>

### 3.1.5.9 Study Limitations

<a id="topic-3.1.5.9-1"></a>

#### Summary: study limitations

VX20-147-008 enrolled healthy adults at one United States site and tested single doses of 90 to 165 mg and multiple doses of 60 to 120 mg once daily, above the 15 mg and 45 mg once daily doses being evaluated in the phase 2/3 trial, with multiple dosing limited to 14 days. Two of its MAD cohorts were stopped early by sponsor decision: 12 participants after an ECG finding attributed to equipment malfunction and 9 participants because of possible COVID-19 exposure, and both cohorts were repeated with new participants. The Study 2 MAD adverse event table therefore excludes these cohorts and has 9 participants in each dose group and 9 receiving pooled placebo, while the pooled adverse event table includes them. Across both phase 1 studies, 128 of 134 participants receiving inaxaplin (95.5%) were male, which the authors attribute to the exclusion of women of childbearing potential. Pharmacokinetic parameter estimates appear only in online supplementary tables, and the trials were designed and funded by Vertex Pharmaceuticals.

Source: [Egbuna et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11006409/)

<a id="topic-3.1.5.9-2"></a>

#### Predominantly male participants

> “A limitation of these studies, like most phase 1 studies, is that participants were predominantly men (owing to exclusion of women of childbearing age).”

Source: [Egbuna et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11006409/)

<a id="topic-3.1.5.9-3"></a>

#### Interrupted and repeated MAD cohorts

> “The majority of treatment discontinuations occurred in two MAD cohorts of Study 2 and were due to sponsor decision (21 participants).”
> “The inaxaplin 60 mg once daily and 90 mg once daily MAD cohorts in Study 2 were repeated with a distinct set of participants.”

Source: [Egbuna et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11006409/)

<a id="topic-3.1.5.9-4"></a>

#### Sponsor funding and employment

> “These studies were supported by Vertex Pharmaceuticals.”
> “Drs. Ogo Egbuna, George Manos, Simon Tian, and Fanuel Hagos are employees of Vertex Pharmaceuticals and own stock or stock options in the company.”

Source: [Egbuna et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11006409/)

## Related pages
- [Inaxaplin (VX-147): APOL1-mediated kidney disease](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Terms and abbreviations](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/terms-and-abbreviations.md)
- [Inaxaplin (VX-147): APOL1-mediated kidney disease](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/executive-summary) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/executive-summary.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Product information and disease description](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/product-information-and-disease-description.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Clinical evidence](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/clinical-evidence.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Economic information and modeling report](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/economics) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/economics.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: References](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/references) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/references.md)
